scispace - formally typeset
E

Eduardo Azziz-Baumgartner

Researcher at Centers for Disease Control and Prevention

Publications -  5
Citations -  1627

Eduardo Azziz-Baumgartner is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Influenza A virus & Incidence (epidemiology). The author has an hindex of 5, co-authored 5 publications receiving 1108 citations. Previous affiliations of Eduardo Azziz-Baumgartner include International Centre for Diarrhoeal Disease Research, Bangladesh.

Papers
More filters
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Ting Shi, +138 more
- 02 Sep 2017 - 
TL;DR: In this paper, the authors estimated the incidence and hospital admission rate of RSV-associated acute lower respiratory infection (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions.
Journal ArticleDOI

The role of temperature and humidity on seasonal influenza in tropical areas: Guatemala, El Salvador and Panama, 2008-2013

TL;DR: The findings highlighted the association between influenza activity and specific humidity in these 3 tropical countries: Guatemala, El Salvador and Panama and negative association was found in the more subtropical Guatemala, similar to temperate regions.
Journal ArticleDOI

Estimated incidence of influenza-virus-associated severe pneumonia in children in El Salvador, 2008-2010

TL;DR: Influenza-virus-associated severe pneumonia occurred frequently among young Salvadorian children during 2008-2010, and antigens in northern and southern hemisphere influenza vaccine formulations corresponded to circulating strains.
Journal ArticleDOI

Demographic and clinical characteristics of deaths associated with influenza A(H1N1) pdm09 in Central America and Dominican Republic 2009–2010

TL;DR: The pandemic killed young adults, pregnant women and those with pre-existing medical conditions, most sought care too late to fully benefit from oseltamivir, and countries review antiviral treatment policies for people at high risk of developing complications.